Jul 21, 2026 · 33 min · 13 segments
Join us for bi-weekly episodes on gynecologic cancer or check out our episode archive and show notes at readysetgyo.com. Follow us on…
Maya GrossHost
As a reminder from our last episode, platinum-resistant disease is defined as recurrence of disease within six months of finishing your original or most recent platinum therapy, and platinum refractory indicates progression of disease while on initial or first-line treatment of platinum.
In general, because of these poor responses, retreatment with a platinum compound is not recommended.
Median progression-free survival is unfortunately low with retreatment of platinum-resistant tumors.
It's quoted at typically five to six months, with response rates that are usually either partial response or clinically stable disease between 10 to 30%.
Historically, life expectancy for these patients was about a year, but we have promising results with newer therapies, resulting in patients living longer.
For platinum-resistant disease, options include systemic therapy or best supportive care.
Systemic therapy can include therapy on clinical trial, cytotoxic chemotherapy, or targeted therapies.
Regardless of the choice for re-treatment therapy, re-evaluation should occur after two to four cycles to determine if patients are deriving a benefit.
For patients who progress on two consecutive chemotherapy regimens without clinical benefit, the NCCN states that these patients may not benefit from additional therapy.
As a reminder from our last episode, platinum-resistant disease is defined as recurrence of disease within six months of finishing your original or most recent platinum therapy, and platinum refractory indicates progression of disease while on initial or first-line treatment of platinum.
In general, because of these poor responses, retreatment with a platinum compound is not recommended.
Median progression-free survival is unfortunately low with retreatment of platinum-resistant tumors.
It's quoted at typically five to six months, with response rates that are usually either partial response or clinically stable disease between 10 to 30%.
Historically, life expectancy for these patients was about a year, but we have promising results with newer therapies, resulting in patients living longer.
For platinum-resistant disease, options include systemic therapy or best supportive care.
Systemic therapy can include therapy on clinical trial, cytotoxic chemotherapy, or targeted therapies.
Regardless of the choice for re-treatment therapy, re-evaluation should occur after two to four cycles to determine if patients are deriving a benefit.
For patients who progress on two consecutive chemotherapy regimens without clinical benefit, the NCCN states that these patients may not benefit from additional therapy.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.